South Korean (KOSPI) Pharma Industry Analysis

Industry Valuation and Performance

Has the South Korean Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 12 Aug 2026	₩57.5t	₩32.6t	₩2.1t	9.9x	27.4x	1.8x
Fri, 10 Jul 2026	₩52.5t	₩32.6t	₩2.1t	10.1x	25x	1.6x
Sun, 07 Jun 2026	₩60.7t	₩32.8t	₩2.1t	10.3x	29.2x	1.9x
Tue, 05 May 2026	₩73.1t	₩32.3t	₩1.8t	15.5x	40.8x	2.3x
Thu, 02 Apr 2026	₩83.9t	₩32.2t	₩1.7t	14x	48.8x	2.6x
Sat, 28 Feb 2026	₩94.3t	₩31.4t	₩1.2t	16.5x	79.6x	3x
Mon, 26 Jan 2026	₩74.9t	₩31.4t	₩1.2t	16.1x	63.2x	2.4x
Wed, 24 Dec 2025	₩70.4t	₩31.4t	₩1.2t	17x	59.4x	2.2x
Fri, 21 Nov 2025	₩69.6t	₩31.3t	₩1.1t	18.5x	61.2x	2.2x
Sun, 19 Oct 2025	₩62.2t	₩31.3t	₩1.0t	19.6x	62x	2x
Tue, 16 Sep 2025	₩62.9t	₩31.1t	₩925.9b	19.8x	67.9x	2x
Thu, 14 Aug 2025	₩58.2t	₩30.7t	₩911.5b	19.9x	63.8x	1.9x
Sat, 12 Jul 2025	₩56.9t	₩30.2t	₩914.7b	17.4x	62.2x	1.9x
Mon, 09 Jun 2025	₩53.7t	₩29.9t	₩880.1b	17.1x	61x	1.8x
Wed, 07 May 2025	₩53.5t	₩29.6t	₩984.4b	17.6x	54.3x	1.8x
Fri, 04 Apr 2025	₩52.0t	₩29.5t	₩972.8b	16.4x	53.5x	1.8x
Sun, 02 Mar 2025	₩55.0t	₩29.5t	₩1.0t	12x	54.8x	1.9x
Tue, 28 Jan 2025	₩55.6t	₩29.6t	₩1.0t	11.7x	54.8x	1.9x
Thu, 26 Dec 2024	₩53.5t	₩29.4t	₩989.8b	12.2x	54.1x	1.8x
Sat, 23 Nov 2024	₩51.4t	₩28.9t	₩895.0b	14.2x	57.5x	1.8x
Mon, 21 Oct 2024	₩63.5t	₩28.7t	₩833.2b	15.8x	76.2x	2.2x
Wed, 18 Sep 2024	₩57.2t	₩20.2t	₩806.5b	14.5x	70.9x	2.8x
Fri, 16 Aug 2024	₩54.3t	₩28.5t	₩770.2b	14.8x	70.5x	1.9x
Sun, 14 Jul 2024	₩56.1t	₩28.4t	₩762.2b	13.7x	73.5x	2x
Tue, 11 Jun 2024	₩53.9t	₩30.2t	₩909.9b	13.4x	59.3x	1.8x
Thu, 09 May 2024	₩54.5t	₩29.7t	₩942.4b	17.7x	57.8x	1.8x
Sat, 06 Apr 2024	₩52.2t	₩29.4t	₩922.9b	17.4x	56.6x	1.8x
Mon, 04 Mar 2024	₩52.8t	₩29.6t	₩593.1b	20.3x	89.1x	1.8x
Wed, 31 Jan 2024	₩51.6t	₩29.6t	₩592.3b	22.8x	87.2x	1.7x
Fri, 29 Dec 2023	₩54.8t	₩29.6t	₩588.2b	22.9x	93.1x	1.8x
Sun, 26 Nov 2023	₩49.6t	₩29.6t	₩624.9b	20.5x	79.3x	1.7x
Tue, 24 Oct 2023	₩45.4t	₩29.3t	₩683.3b	15.4x	66.5x	1.5x
Thu, 21 Sep 2023	₩51.5t	₩29.3t	₩683.3b	16.8x	75.4x	1.8x
Sat, 19 Aug 2023	₩50.4t	₩28.8t	₩901.2b	23x	55.9x	1.7x

Current Industry PE

Investors are pessimistic on the South Korean Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 26.9x which is lower than its 3-year average PE of 61.9x.

The 3-year average PS ratio of 1.9x is higher than the industry's current PS ratio of 1.7x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 33% per year over the last three years.
Revenues for these companies have grown 4.2% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Healthcare industry?


KR Market	0.52%
Healthcare	11.15%
Pharma	9.92%
Pharma	9.92%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
A000100 Yuhan	₩83.50k	11.2% +₩628.0b	-26.4%	PE29.8x
A326030 SK Biopharmaceuticals	₩88.35k	7.7% +₩497.3b	-11.8%	PE19.8x
A000250 Sam Chun Dang Pharm	₩186.20k	11.8% +₩458.8b	0.05%	PE426x
A128940 Hanmi Pharm	₩397.50k	4.6% +₩222.1b	41.2%	PE29.3x
A039200 Oscotec	₩38.80k	15.5% +₩198.9b	15.0%	PE26.7x

Mezzion Pharma Co., Ltd. Reports Positive In Vivo Results For Udenafil In ADPKD

Mezzion Pharma Co. Ltd. announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil reduced kidney cyst burden and blood urea nitrogen (BUN), a blood marker linked to kidney function, compared with controls. Both findings were statistically significant and consistent across the treatment groups evaluated. The study also showed evidence of activity on udenafil's intended cyclic guanosine monophosphate (cGMP) signaling pathway in the kidney. In addition, udenafil produced a statistically significant reduction in a preclinical measure of cardiac hypertrophy, or heart enlargement. The study was conducted at Mayo Clinic in Florida, with Fouad T. Chebib, M.D., serving as principal investigator. The results build on two earlier preclinical studies in which udenafil inhibited cyst growth and reduced cyst burden. Across these complementary ADPKD models, udenafil has shown activity on its intended cGMP pathway, reduced measures of cystic disease, and improved a biochemical measure used in kidney assessment. Together, the data support clinical evaluation in people with ADPKD. Udenafil has been studied in multiple clinical programs over approximately 20 years, including studies with multi-year exposure. The consistency across multiple preclinical models supports evaluating udenafil in a well-designed Phase 2b study using established measures of ADPKD progression. Udenafil is being investigated through modulation of the nitric oxide-cGMP pathway, providing a mechanistically distinct therapeutic approach. ADPKD is a progressive genetic kidney disease affecting approximately 1 in 400 to 1,000 people worldwide. As kidney cysts grow, kidney function can decline and ultimately lead to dialysis or kidney transplantation. ADPKD is also associated with cardiovascular and other complications. Mezzion plans to advance udenafil into a Phase 2b study in adults at risk of rapidly progressing ADPKD, subject to finalization of the protocol and receipt of regulatory and ethics approvals. The planned study is expected to evaluate kidney volume and function, disease-related biomarkers, pharmacokinetics, safety, and tolerability. Udenafil is an investigational product and has not been approved by any regulatory authority.

South Korean (KOSPI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Investor sentiment improves as stock rises 18%

Consensus EPS estimates increase by 15%

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 15%

Mezzion Pharma Co., Ltd. Reports Positive In Vivo Results For Udenafil In ADPKD

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 20%

Now 23% overvalued

CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.

New major risk - Share price stability

Now 20% overvalued

ADBiotech Co., Ltd. announced that it has received KRW 13.261700256 billion in funding

New major risk - Revenue and earnings growth

New major risk - Earnings quality